title: Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
abstract: Survivin plays an important role in preventing apoptosis and permitting mitosis, and is highly expressed in various human cancers. EZN-3042 is a locked nucleic acid antisense oligonucleotide (LNA-AsODN) against survivin. We report the effects of EZN-3042 in animal models. In a chemical-induced liver regeneration model, treatment with a mouse homolog of EZN-3042 resulted in 80% down-modulation of survivin mRNA. In A549 and Calu-6 lung xenograft models, treatment with EZN-3042 single agent induced 60% down-modulation of survivin mRNA in tumors and 37-45% tumor growth inhibition (TGI). In Calu-6 model, when EZN-3042 was combined with paclitaxel, an 83% TGI was obtained. EZN-3042 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with docetaxel.
authors.affiliation: Enzon Pharmaceuticals, Inc., Piscataway, New Jersey, USA.
authors.forename: Puja
authors.initials: P
authors.lastname: Sapra
authors.forename: Maoliang
authors.initials: M
authors.lastname: Wang
authors.forename: Raj
authors.initials: R
authors.lastname: Bandaru
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Lee M
authors.initials: LM
authors.lastname: Greenberger
authors.forename: Ivan D
authors.initials: ID
authors.lastname: Horak
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008115:Liver Regeneration / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D020714:Maximum Tolerated Dose; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000378:metabolism; D009841:Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D000077022:Survivin; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: C107489:BIRC5 protein, human; C552302:EZN 3042; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D000077022:Survivin; C477371:locked nucleic acid; D017239:Paclitaxel